European Neuropsychopharmacology

Cholecystokinin in anxiety
pp. 263-280(18)
Authors: van Megen H.J.G.M.; Westenberg H.G.M.; den Boer J.A.; Kahn R.S.

The antinociceptive effect of fluvoxamine
pp. 281-284(4)
Authors: Schreiber S.; Backer M.M.; Yanai J.; Pick C.G.

Piracetam and fipexide prevent PTZ-kindling-provoked amnesia in rats
pp. 285-290(6)
Authors: Genkova-Papazova M.G.; Lazarova-Bakarova M.B.

Behavioral effects of CCK_B receptor ligands in a validated simulation of panic anxiety in rats
pp. 291-298(8)
Authors: Jenck F.; Martin J.R.; Moreau J.-L.

Bupropion induces sniffing: a possible dopaminergic mechanism
pp. 299-303(5)
Authors: Zarrindast M.R.; Hodjati M.R.; Pejhan A.; Soleimannejad E.

Enhancement of antipsychotic-like properties of the dopamine D₂ receptor antagonist, raclopride, by the additional treatment with the 5-HT₂ receptor blocking agent, ritanserin, in the rat
pp. 305-310(6)
Authors: Wadenberg M.-L.; Salmi P.; Jimenez P.; Svensson T.; Ahlenius S.

Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory
pp. 311-316(6)
Authors: Fraser C.M.; Cooke M.J.; Fisher A.; Thompson I.D.; Stone T.W.

Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo
pp. 317-322(6)
Authors: Bergqvist P.B.F.; Hjorth S.; Audet R.M.; Apelqvist G.; Bengtsson F.; Butterworth R.F.

Flumazenil attenuates the pituitary response to CRH in healthy males
pp. 323-325(3)
Authors: Strohle A.; Wiedemann K.